Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bicalutamide (ICI-176334) 是一种具有口服活性的非甾体雄激素受体拮抗剂,可研究前列腺癌。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
50 mg | ¥ 415 | 现货 | ||
100 mg | ¥ 634 | 现货 | ||
200 mg | ¥ 918 | 现货 | ||
500 mg | ¥ 1,728 | 现货 | ||
1 g | ¥ 2,698 | 现货 |
产品描述 | Bicalutamide (ICI-176334), a synthetic, nonsteroidal antiandrogen, competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. |
靶点活性 | Androgen receptor:0.16 μM |
体内活性 | Bicalutamide在规定的次最大剂量下可将肿瘤生长速率降低79%。Ridaforolimus与bicalutamide联合使用展示出更加有效的抗肿瘤活性。该联合疗法亦具有良好的耐受性,治疗过程中体重无显著变化。在接受联合治疗的小鼠中,血浆PSA水平与肿瘤生长紧密相关。[3] |
激酶实验 | Whole-cell competitive binding assays: Whole-cell competitive binding assays are performed in LNCaP/AR(codon-switch) (LNCaP/AR(cs)) (harbors a mixture of exogenous wild-type AR and endogenous mutant AR (T877A)) and cells propagated in Iscove's or RPMI media supplemented with 10% fetal bovine serum, or during the assay with 10% charcoal-stripped, dextran-treated fetal bovine serum (CSS). Cells are pre-incubated with 18F-FDHT, increasing concentrations (1pM to 1 μM) of cold Bicalutamide are added, and the assay is performed to measure specific uptake of 18F-FDHT (4). IC50 values are determined using a one site binding model with least squares curve fitting and R2 > 0.99. |
细胞实验 | Exponentially growing C4-2 cells are plated into two 96-well plates and incubated overnight at 37 ?C. Twenty-four hours later one plate is aspirated and stored at -80 ?C and the other treated with 10-fold serial concentrations of ridaforolimus (1000 nM to 0.0001 nM) or vehicle (ethanol). Following 72 hours culture at 37 ?C, the plates are assessed simultaneously for cell growth using the Cy qUANT Cell Proliferation Assay kit. Bicalutamide and Ridaforolimus combination proliferation assays are performed similarly except cell growth is determined as the change in cell number between vehicle control and compound treated cells after 72 hours in culture.(Only for Reference) |
别名 | 比卡鲁胺, ICI-176334 |
分子量 | 430.37 |
分子式 | C18H14F4N2O4S |
CAS No. | 90357-06-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 43 mg/mL (100 mM)
Ethanol: 4.3 mg/mL (10 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.3236 mL | 11.6179 mL | 23.2358 mL | 58.0896 mL |
5 mM | 0.4647 mL | 2.3236 mL | 4.6472 mL | 11.6179 mL | |
10 mM | 0.2324 mL | 1.1618 mL | 2.3236 mL | 5.809 mL | |
DMSO | 20 mM | 0.1162 mL | 0.5809 mL | 1.1618 mL | 2.9045 mL |
50 mM | 0.0465 mL | 0.2324 mL | 0.4647 mL | 1.1618 mL | |
100 mM | 0.0232 mL | 0.1162 mL | 0.2324 mL | 0.5809 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Bicalutamide 90357-06-5 Autophagy Endocrinology/Hormones Androgen Receptor 比卡鲁胺 cancer androgen castration-resistant ICI 176334 receptor prostate cancer Inhibitor prostate ICI-176334 inhibit ICI176334 anti-androgen non-steroidal inhibitor